Corcept Therapeutics (CORT) Earning Somewhat Favorable Press Coverage, Analysis Finds

News stories about Corcept Therapeutics (NASDAQ:CORT) have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Corcept Therapeutics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.112689278953 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Corcept Therapeutics (CORT) traded down $0.17 during midday trading on Friday, hitting $17.58. The company had a trading volume of 531,106 shares, compared to its average volume of 1,290,000. The firm has a market cap of $2,010.00, a PE ratio of 60.62 and a beta of 2.04. Corcept Therapeutics has a 1 year low of $6.70 and a 1 year high of $20.77.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.02). The firm had revenue of $42.70 million during the quarter, compared to analyst estimates of $41.64 million. Corcept Therapeutics had a net margin of 27.28% and a return on equity of 58.17%. The firm’s revenue for the quarter was up 96.8% compared to the same quarter last year. During the same period last year, the company earned $0.02 earnings per share. research analysts predict that Corcept Therapeutics will post 0.47 earnings per share for the current fiscal year.

Several research analysts have recently issued reports on CORT shares. BidaskClub raised Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 18th. Piper Jaffray Companies set a $30.00 price objective on Corcept Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Stifel Nicolaus initiated coverage on Corcept Therapeutics in a research report on Thursday, August 31st. They set a “buy” rating and a $20.00 price objective for the company. Finally, Zacks Investment Research cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $18.20.

In other Corcept Therapeutics news, Director G Leonard Baker, Jr. sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $17.59, for a total transaction of $527,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 19.20% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Corcept Therapeutics (CORT) Earning Somewhat Favorable Press Coverage, Analysis Finds” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2017/11/27/corcept-therapeutics-cort-earning-somewhat-favorable-press-coverage-analysis-finds.html.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply